Will be lighter on regulation but heavy on execution: Drug Controller

On the drug approvals, Dr Rajeev Sigh Raghuvanshi, the DCGI highlighted innovative therapies that were both impactful in terms of health outcomes and also available at an affordable price. He also underlined the need for risk money that can back Indian drug makers in their journey beyond generics and towards innovation and drug discovery research.